|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
Lexicon Pharmaceuticals, Inc. (LXRX) Reports on Clinical Program Status and 2012 Third Quarter Results
11/6/2012 10:31:04 AM
THE WOODLANDS, Texas, Nov. 6, 2012 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (LXRX), a biopharmaceutical company focused on discovering breakthrough treatments for human disease, today updated its drug development progress and reported financial results for the three and nine months ended September 30, 2012.
"Our positive results from a second Phase 2 study of telotristat etiprate provide further evidence of its potential to benefit patients with carcinoid syndrome," said Dr. Arthur T. Sands, president and chief executive officer of Lexicon. "The initiation of a registrational Phase 3 study of telotristat etiprate in carcinoid syndrome patients represents another significant milestone in the advancement of Lexicon's clinical pipeline."
|
|
|
|
|
|
|
|
|
|
|